Abstract: Provided herein, in some aspects, are delivery vehicles comprising a ceramide and an agent to be delivered attached to the ceramide. In some embodiments, the ceramide does not comprise a fatty acid (i.e., is a sphingosine). In some embodiments, the ceramide comprises a fatty acid. In some embodiments, the ceramide is a glycoceramide. In some embodiments, the agent is attached to the ceramide covalently (e.g., via a linker). In some embodiments, the agent to be delivered is a therapeutic agent. The ceramide is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the ceramide described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the ceramide delivery vehicle are also provided.

Abstract: The present invention relates to an immune checkpoint inhibitor conjugated with an sonosensitizer, a use thereof, and the like. The immune checkpoint inhibitor conjugate conjugated with an sonosensitizer according to the present invention has selectivity for tumors with respect to targeted therapy and specifically responds to ultrasonic waves, and thus can be used to produce drugs for diagnosing and treating cancer. Particularly, the conjugate of the present invention exhibits excellent solubility and stability in an aqueous solution, and provides excellent anticancer effects as compared with simple immune checkpoint inhibitors, and therefore, is expected to be useful as a novel drug for treating cancer.

Abstract: Polymeric drugs for disease therapy are provided. The repeat units of the polymers comprise at least one chemotherapeutic agent, e.g. a cancer drug. The linkages between repeat units are hydrolysable under physiological conditions, e.g. at targeted sites in vivo. Nanoparticles formed from the polymers are also provided.

Abstract: Prodrugs that target the low-density lipoprotein receptor (LDLR) and that comprise acid and/or enzyme cleavable acetal- or oxybenzyloxy-linked carbonate or carbamate bonds are described. Also described are core-shell nanoparticles comprising metal-organic framework cores or nanoscale metal bisphosphate coordination polymer cores, and lipid coating layers containing the prodrugs. The nanoparticle core can optionally contain one or more hydrophilic chemotherapeutic agents. The prodrugs and nanoparticles can be used in methods of treating cancer. For instance, the presently disclosed nanoparticles can be used for the co-delivery of multiple chemotherapeutic agents in methods providing increased accumulation of chemotherapeutic agents to a tumor compared to delivery of mixtures of free chemotherapeutic agents.

Abstract: The present disclosure relates to transcription modulator molecules having a first terminus, a second terminus, and an oligomeric backbone and methods for treating Huntington's disease.

Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.

Abstract: The present invention relates to a pharmaceutical composition that is for treating pancreatic cancer and contains a nucleic acid complex as an active ingredient, and more specifically, to a pharmaceutical composition that is for preventing or treating pancreatic cancer and contains a nucleic acid complex in which a bioactive peptide nucleic acid, having a sequence binding to the KRAS gene, and a carrier peptide nucleic acid are complementarily bound. The nucleic acid complex according to the present invention has excellent cell permeability and intracellular activity, and can effectively inhibit the expression of the KRAS gene and subtype genes thereof, and is thus useful for the prevention or treatment of pancreatic cancer.

Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.

Abstract: The invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-phenyl-2-aminobenzazepine derivatives. The invention also provides 8-phenyl-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

Abstract: Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.

Abstract: This disclosure generally relates to novel processes for the preparation of drug linker compounds and compositions comprising such drug linker compounds. The presently disclosed methods for synthesizing Fmoc-Val-Cit-PABOH and related compounds have also been found to minimize formation of diastereomeric impurities.

Abstract: Disclosed herein are glycoconjugates having a cell-binding agent, such as an antibody, conjugating to a payload, such as a drug. The drug is conjugated to the cell-binding agent through an oligosaccharide linker. The glycoconjugates conjugated through the oligosaccharide linkers disclosed herein exhibit improved properties over prior glycoconjugates.

Abstract: Described herein is hydrogel composition, wherein the hydrogel is loaded with bacterial particles including a gasdermin D (GSDMD) protein cage conjugated to a surface thereof, and nanoparticles loaded with an ESCRT inhibitor. The hydrogel can be formulated as an injectable hydrogel for treatment at the site of a primary or metastatic tumor. Alternatively, the hydrogel can be formulated as a thermosensitive hydrogel for implantation at the site of an inoperable cancer.

Abstract: Exosomes that express peptides in CD9 proteins, and smart exosomes that co-express two peptides incorporated into CD9 proteins to home delivery of the exosomes to a desired target and evade phagocytosis by macrophages, are described. Provided are exosomes useful for delivering drugs to desired targets. The exosomes comprise drugs, such as chemotherapeutic drugs, encapsulated in their core. The targets include pancreatic cancer cells.

Abstract: The invention relates to a method for attaching a non-soluble active pharmaceutical ingredient (API) to a micro sphere produced by thermally induced phase separation (TIPS) comprising: i) mixing the micro sphere with an aqueous solution to form a first composition; ii) dissolving the non-soluble API in a first solvent and subsequently adding the non soluble API dissolved in the first solvent to the first composition to form a second composition; and iii) mixing the second composition. The invention further relates to a micro sphere produced by thermally induced phase separation which has a non-soluble API bound to its surface and a composition comprising said micro sphere for use in therapy.

Abstract: Provided herein are nucleic acid trans-splicing molecules (e.g., pre-mRNA trans-splicing molecules (RTMs); RNA exon editing molecules) capable of correcting mutations in the ABCA4 gene. Such molecules are useful in the treatment of disorders such as ABCA4-associated retinal dystrophies (e.g., Stargardt Disease or cone-rod dystrophy). Also described herein are methods of using the nucleic acid trans-splicing molecules described herein to correct mutations in ABCA4, thereby treating disorders associated with mutations in ABCA4 and use of the nucleic acid trans-splicing molecules described herein for treating disorders associated with mutations in ABCA4 and in the preparation of medicaments for the treatment of disorders associated with mutations in ABCA4.

Abstract: The invention provides, inter alia, systems and associated methods, for modifying DNA, such as the genome of a cell. The systems, in certain embodiments, encompass one or more tissue-specific expression-control sequences, such as promoters and microRNA binding sites in addition to a transposase (or a nucleic acid encoding the same) and a template nucleic acid comprising a sequence to be inserted into the genome of a cell, tissue, or subject.

Abstract: Disclosed are a composition and method of treating or preventing cardiomyopathy in a human subject. In some embodiments, the method comprises delivering a therapeutic dose of a gene therapy vector to cardiomyocytes of the human subject, wherein the gene therapy vector comprises a nucleic acid sequence encoding for PKP2.

Abstract: In some aspects, cardiac-specific expression cassettes are provided herein. In some aspects, provided herein is an expression cassette comprising a polynucleotide sequence encoding a gene product for therapy of a heart disease, wherein the polynucleotide sequence is operably linked to promoter (e.g., a cardiac-specific promoter), and optionally an enhancer (e.g., a cardiac-specific enhancer). In some aspects, the disclosure provides recombinant adeno-associated virus (rAAV) virions, comprising a capsid protein and a viral genome comprising an expression cassette comprising a polynucleotide sequence encoding a therapeutic gene product, e.g., dwarf open reading frame (DWORF) polypeptide, operably linked to a promoter, the expression cassette flanked by inverted terminal repeats. The disclosure further provides pharmaceutical compositions and methods of treating or preventing heart disease.

Abstract: Provided herein are methods and compositions for suppressing or preventing an infection in a subject infected by a pathogen or decreasing organ or tumor tissue fibrosis that involve administering to the subject a composition that includes a therapeutically effective amount of a p53 therapy. Also disclosed are methods of suppressing tumor stroma by contacting the tumor stroma with the p53 therapy, wherein the p53 suppresses tumor stroma activities.

Abstract: This disclosure relates to the field of fluorescent dyes, and in particular, compositions and methods for increasing fluorescent signals and the reduction of fluorescent quenching.

Abstract: Provided herein are, inter alia, pH-triggered compounds and compositions comprising one or more peptides that are capable of inserting into a lipid bilayer below a certain pH. Treatment, imaging, diagnostic, and other uses of such compounds and compositions are also provided.

Abstract: A nano- or microparticle comprising a matrix consisting of or comprising at least one polyvinyl alcohol (PVA) and dispersed therein, ferrite, and a method for producing the same. Further, the use of these nano- or micro-particles for the preparation and the implementation of devices that can be detected by giant magnetoresistance sensors (GMR sensors) as biological diagnostic tools.

Abstract: Disclosed herein is the use of compounds having the formulae (I) and (II), as described herein, as theranostic agents.

Abstract: Provided are a compound as represented by general formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, wherein C is a chelator unit; AB is an albumin binding unit; and FAPI is a fibroblast activation protein inhibitor unit. Also provided are a chelate of the above-mentioned compound and a radioactive nuclide, a pharmaceutical composition and the use thereof as a fibroblast activation protein inhibitor for the diagnosis and treatment of diseases.

Abstract: The present disclosure generally relates to a radiopharmaceutical composition comprising 177Lu-PSMA I&T. The composition is formulated as a solution for injection and the solution is suitable for administration more than 72 hours after formulation. The composition may include ascorbic acid and have a pH of 3.5 to 4.5 in solution. In some examples, the composition is suitable for administration to a human patient in need thereof at least 90 hours after formulation, and the composition has a radiochemical purity of 95% or greater at administration.

Abstract: Embodiments of the synthesis, radiolabeling and biological applications of an activatable tracer that undergoes intramolecular cyclization and aggregation upon activation by cleavage of a blocking moiety are provided. The probes of the disclosure allow for target-controlled self-assembly of small molecules in living subjects for imaging and drug delivery. The aggregated nanoprobes of the disclosure may be detectable optically, by PET detection, magnetic resonance imaging, and the like depending on the detectable reporter attached to the nanoprobe.

Abstract: The present invention is directed to methods for providing a peptide receptor radiotherapy treatment recommendation for a subject having a neuroendocrine tumor by determining the expression level of each of at least 9 biomarkers comprising ARAF1, BRAF, KRAS, RAF-1, ATP6V1H, OAZ2, PANK2, PLD3, and ALG9. In some embodiments, the methods can further include determining the expression level of each of NAP1L1, NOL3, and TECPR2.

Abstract: Described herein are compositions and methods for treating cancer using a RIG-I agonist precursor comprising single-stranded 5? uncapped triphosphate or biphosphate antisense oligonucleotide having a sequence complementary to an endogenous miRNA; optionally wherein the compositions and methods comprise a nanoparticle for targeted delivery of the RIG-I agonist precursor and a radiolabel to a tumor micro environment.

Abstract: Process for making active carriers, including nanospheres of inorganic material, organofunctional material, activated powder including radionuclides, a layer including the organofunctional material and activated powder deposited on the nanospheres surface, the process including the nanospheres in inorganic material, crushing and subsequent grinding of a matrix to obtain a powder, preparing the organofunctional material, synthesis of inactive carriers, including the nanospheres, a coating including the organofunctional material and the powder deposited on the nanospheres surface, the synthesis including incorporating the powder into the organofunctional material, depositing organofunctional material on the nanospheres surface to achieve the coating, synthesis of the active carriers, including activating the inactive carriers by generating radionuclides in the powder, and transforming the powder into activated powder, and consequently of the coating into the layer and transforming the inactive carriers into act

Abstract: The invention relates to a modular irradiation device having a main module and at least one support cassette, the support cassette being insertable into a receptacle of the main module. The support cassette has at least one pump, and the main module has at least one pump actuator, these being arranged such that the pump is actuatable with the pump actuator when the support cassette is inserted into the receptacle of the main module.

Abstract: Reusable instrumentation, such as a medical instrument or tool, is decontaminated by applying pressure waves from multiple shockwave applicators and/or reflectors.

Abstract: An Air Quality Control Lighting Device incorporating a purification device in combination with a lighting device having a LED light panel, a cover installed above the light panel, the interior of the cover forms a cavity that encloses an air UV purification device, and the air UV purification device consisting of a plurality of UV lamps mounted atop the LED light panel.

Abstract: A sterilization system of an embodiment includes a light source unit, a horizontal angle adjustment unit and/or a vertical angle adjustment unit, and a controller. The light source unit emits ultraviolet rays in a radiating form. The horizontal angle adjustment unit adjusts a horizontal angle of the light source unit by causing rotation of the light source unit in a horizontal direction. The vertical angle adjustment unit adjusts a vertical angle of the light source unit by causing rotation of the light source unit in a vertical direction. The controller reads setting information including the horizontal angle and/or the vertical angle, controls the rotation caused by the horizontal angle adjustment unit and/or the vertical angle adjustment unit, and controls irradiation of the ultraviolet rays by the light source unit.

Abstract: A sanitization system includes a plurality of light distribution hubs spaced along a longitudinal frame. Each hub includes a plurality of light emitting modules (e.g., LED chip-on-board) configured to deliver a predetermined type of light (e.g, UVC) to a target surface for a variable or predetermined amount of time at a variable or predetermined intensity to at least partially disinfect and/or sanitize the target surface. The target surface may be an interior surface of a medical imaging device, such as an inwardly facing bore surface and/or patient support surface of an MRI or CT scanner.

Abstract: Provided is a method of inactivating bacteria and/or viruses in a target space using ultraviolet light having wavelengths less than 240 nm, while suppressing the progress of deterioration of a plant. The present invention is a method of inactivating bacteria and/or viruses in a target space where a plant is placed, the method includes a process (a) of irradiating the target space with ultraviolet light having light intensity in a wavelength band belonging to within a range from 190 nm to 235 nm from an ultraviolet light source during a time period when the plant is irradiated with sunlight or visible light from an illumination light source.

Abstract: A disinfectant transmissive material incorporated into a case for a mobile device or a supporting surface of a disinfecting charger to enable disinfection of hard to reach areas. The case can be self-disinfecting. The disinfecting charger can have monitoring and safety systems that detect proximity and provide user feedback on safety, disinfection, and charge status along with automatic interlocks to protect the user from overexposure to disinfectant.

Abstract: Disclosed is a shoe care apparatus including: a cabinet; a chamber provided in the cabinet for accommodating a shoe; a machine room provided to accommodate a heat pump which heats the air supplied to the chamber and dehumidifies the air discharged from the chamber; an air supply duct which connects the chamber to the machine room; an air supply port which is provided in the sidewall of the chamber such that the air flowing along the air supply duct is supplied into the chamber through the air supply port; a support member which is provided on the sidewall of the chamber to be adjacent to the air supply port; and a shoe hanger which includes a pair of support arms that are accommodated in the chamber, that are configured to be inserted into , is detachably installed on the support member, and has a hollow inside such that the air supplied from the air supply port may flow therein, wherein the shoe hanger has a sterilization device provided in the hollow inside and the support member is provided with a power su

Abstract: A method and a system for adjusting a cycle time of a treatment process for an object are provided. The method comprises introducing a treatment agent comprising hydrogen peroxide into a chamber comprising the object and conducting a first treatment stage therein. A hydrogen peroxide vapor concentration in the chamber is measured utilizing a sensor during the first treatment stage to obtain a measured concentration. The measured concentration is compared to a threshold concentration value to obtain a comparison value. A cycle time of the first treatment stage is adjusted based on the comparison value.

Abstract: An embodiment for decontaminating transportation vehicles is provided. The embodiment may include receiving GPS data and real-time and historical data relating to contamination. The embodiment may also include identifying a route and location of the transportation vehicle. The embodiment may further include predicting one or more target areas to decontaminate. The embodiment may also include placing one or more decontamination devices at the target areas. The embodiment may further include identifying one or more parts of the transportation vehicle requiring decontamination. The embodiment may also include in response to determining at least one type of contamination is airborne, activating the one or more decontamination devices to increase air pressure inside the transportation vehicle and releasing the air pressure when a door is opened.

Abstract: An excimer bulb assembly, with an excimer bulb, at least one integral captured reflector, and an integral filter such that the excimer bulb only emits substantial UV radiation between 200 nm and 230 nm, using a filter that passes light from about 200 nm to 234 nm (+/?2 nm).

Abstract: A plug-in diffuser, such as a fragrance diffuser, has a configuration that preserves a substance to be diffused, such as a fragrance. A configuration of a body of the plug-in diffuser may prevent the substance to be diffused from contacting an electrical plug of the fragrance diffuser and/or from entering into an electrical outlet. A receptacle in a top of the body of the plug-in diffuser may receive a reservoir of the substance to be diffused. A canopy assembled with the body may provide decorative effects (e.g., appearance, lighting, etc.).

Abstract: An electronic scented candle is described that includes a movable flame-shaped component, a shell including an installation chamber, a fragrance container that is removably positioned inside the installation chamber and a scent chamber. An electric fan is positioned within the shell to drive the air into the scent chamber and a scent outlet coupled to the scent chamber to allow the fragrance material to leave the scent chamber and to reach an external environment of the electronic scented candle. The electronic candle also includes a receptacle for connecting a power cord on a bottom surface of the electronic candle. The bottom surface includes a plurality of protruding stands that provide a space to allow the power cord to be connected to the receptacle and be routed below the bottom surface.

Abstract: A method of emitting a volatile material from a volatile material dispenser includes the steps of identifying a first vapor pressure of a first fragrance characteristic of the volatile material, identifying a second vapor pressure of a second fragrance characteristic of the volatile material that is different than the first vapor pressure, heating the volatile material to a first temperature associated with the first fragrance characteristic, and heating the volatile material to a second temperature associated with the second fragrance characteristic that is different than the first temperature.

Abstract: Scented air filters for homes and vehicles are provided. The device includes a frame and a plurality of filter layers. The plurality of filter layers is connected to the frame. The plurality of filter layers is configured to filter the air that passes through each layer. The frame is designed to resemble standard home or car cabin air filters. The plurality of filter layers further includes a scented material disposed of thereon. The scented material is designed to enhance the scent of the air that is pushed through the air filter.

Abstract: An external ventilation system of a capsule pod sleeping chamber that includes a wall with an exterior side that faces a communal space and an interior side that faces an interior of the capsule pod sleeping chamber. The external ventilation system further includes a duct to route first air out from the communal space to an area separated from air of the capsule pod sleeping chamber, where the duct is located between the exterior side and the interior side, and there is an aperture located on the exterior side opening into the duct.

Abstract: A sterilization box for treating room air is described. The air drawn into the sterilization box is irradiated with UV radiation, such as is provided from UV LED chips. The air may be drawn into the sterilization box by under-pressure within the box created by fans at the exit ports of the box. The air may be drawn into a first chamber of the box where it is treated with one wavelength of UV radiation and then passed to a second chamber, where it is treated with a second wavelength of UV radiation. After the air is sterilized, it can be put back into the room or building in which the fixture is placed.

Abstract: Provided are an air purification module and an air purification system including the same. The air purification module is configured to purify influent unpurified air and discharge purified air and includes: a catalyst filter including a photocatalyst and an oxidation catalyst; and a light-emitting heat source disposed adjacent to the catalyst filter, wherein the light-emitting heat source irradiates, to the catalyst filter, light for activating the photocatalyst, and provides heat to activate the oxidation catalyst, and a temperature of the light-emitting heat source is higher than a temperature of the unpurified air.

Abstract: An air purification system has an air inlet far and an air outlet, with a conduit between the air inlet and the air outlet. Disposed within the conduit in the direction of air flow, there is included at least one ionizer creating a first air ionisation zone within which, in use, aerosols and/or airborne particles in incoming air are ionised become charged. In the conduit there is further a charge reduction stage creating a first charge reduction zone that includes a charge reduction device located across a flow path of the airflow, terminating the air ionisation zone, such that the wherein as charged aerosols and/or particles pass therethrough, and in passing through the charge reduction stage the charged aerosols and/or particles are attracted to the charge reduction stage and on contact with the charge reduction stage become at least partially discharged.

Abstract: The invention is directed a hemostatic foam, to a process for preparing a biodegradable hemostatic foam, and to the use of said foam. The hemostatic foam comprises a blend of a chitosan hemostatic agent and a polymer, which polymer provides the foam with a porosity of 85-99% and a foam density of 0.01-0.2 g/cm3.